Company: RAPT Therapeutics
Job title: Chief Scientific Officer
Dirk G. Brockstedt is Senior Vice President of Biology and has more than 20 years of experience in the fields of immunology and oncology originating with his PhD from the University of Kiel and Stanford University. Dirk joined RAPT Therapeutics in January 2018, bringing a wealth of experience in immunology at all stages of discovery, translational and clinical development. He joined RAPT from Aduro Biotech, where he served as Executive Vice President of Research and Development. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation and at Aventis in the immunotherapy and anti-angiogenesis groups. Dr. Brockstedt co-authored over 40 scientific papers and is a named inventor on seven issued patents and several pending applications.
Case Study by RAPT Therapeutics: Optimise RPT193; A Potent, Selective Oral CCR4 Antagonist for the Treatment of Atopic Dermatitis 10:15 am
• Exploring the function of Th2 cells in AD and the influence of CCR4-mediated Th2 migration to the disease • Showcasing the innovative oral CCR4 antagonist: RPT193 • Illustrating the preclinical efficacy of RPT193 in numerous Th2 driven allergic disease mouse models • Optimising and evaluating the clinical development strategy for RPT193Read more
day: Day Two